Drug intelligence / Profile preview

namilast

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

Namilast (BI 1015550) is an oral, small-molecule preferential inhibitor of phosphodiesterase 4B (PDE4B) developed by Boehringer Ingelheim. It is designed to address the inflammatory and fibrotic pathways involved in lung diseases. By inhibiting PDE4B, namilast increases intracellular levels of cyclic adenosine monophosphate (cAMP), which modulates various cellular processes to reduce lung tissue scarring and inflammation. It is currently in Phase 3 clinical development for idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILD), including pediatric populations.

Other names: namilast

Targets

PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4C (Phosphodiesterase 4C)PDE4D (Phosphodiesterase 4D)PDE4A

Beyond the preview

Go deeper on namilast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on namilast.

Explore the full profile